This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxford BioTherapeutics Appoints Bryan G. Morton As Chairman

OXFORD, England, June 26, 2013 /PRNewswire/ --

Oxford BioTherapeutics (OBT), a global biotechnology company developing first-in-class, antibody-based cancer medicines to fulfil unmet patient needs, today announces the appointment of Bryan G. Morton as the Company's new Non-executive Chairman.

Bryan Morton has over 30 years experience as a successful entrepreneur and senior manager in the pharmaceutical industry. Morton was previously CEO of EUSA Pharma, a global speciality oncology company, which was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) in 2012 for $700 million.  After founding EUSA in 2005, Morton was able to fund the company's growth by raising $265 million from several prominent life science investors, including Goldman Sachs, Essex Woodland, 3i, Advent, SV Life Sciences, Neomed and Novaquest. In 2003, Morton founded and was appointed CEO of Zeneus Pharma Ltd (2003), a European speciality oncology and critical care company. He sold Zeneus to Cephalon (Nasdaq: CEPH) for $360 million, delivering generous returns to Apax Partners, an early investor. Prior to running Zeneus, Morton was president of Convatec, EMEA (Bristol Myers Squibb, NYSE: BMY) and spent over 20 years in positions of increasing responsibility at Merck & Co (NYSE: MRK).

Christian Rohlff, CEO and Founder of OBT, commenting on today's announcement said: "I am delighted that Bryan has decided to accept the position of Chairman at OBT. His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs. I would like to take this opportunity to thank Dr Michael Moore for his wise counsel and support over the last three and a half years. During this time we have built OBT into a leading global mAb developer and have signed important development alliances with Menarini and Sanofi."

Bryan G. Morton, Chairman of OBT, said: "I am glad to have this opportunity to work with Christian and the team at OBT. I have been very impressed at how they have leveraged the unique OGAP database to generate their own exciting pipeline of antibody medicines and to sign collaborations with a broad range of companies focused on developing new treatments for cancer. I am looking forward to using my experience in building successful specialty pharma businesses to allow me to make an important contribution to OBT as it enters the next phase of its corporate development."

About Oxford BioTherapeutics

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs